BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 16405018)

  • 1. [Morphofunctional characteristics of microvessels in serous tumors of the ovaries].
    Mikhaleva LM; Moroz EA; Barkhina TG; Cherniaev AL; Samsonova MV; Solomatina AA
    Arkh Patol; 2005; 67(6):28-31. PubMed ID: 16405018
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fascin expression in serous tumors of ovary correlates with aggressiveness of malignancy.
    Wen YH; Yee H; Goswami S; Shukla PS
    Int J Gynecol Pathol; 2009 Mar; 28(2):187-92. PubMed ID: 19188814
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinicopathological significance of DEK overexpression in serous ovarian tumors.
    Han S; Xuan Y; Liu S; Zhang M; Jin D; Jin R; Lin Z
    Pathol Int; 2009 Jul; 59(7):443-7. PubMed ID: 19563407
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative evaluation of blood vessels in serous tumors of the ovaries by color Doppler mapping and morphometry.
    Mikhaleva LM; Moroz EA; Solomatina AA; Stepanov KI
    Bull Exp Biol Med; 2002 Feb; 133(2):188-91. PubMed ID: 12428292
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Morphometry and digital AgNOR analysis in cytological imprints of benign, borderline and malignant serous ovarian tumours.
    Stemberger-Papić S; Stanković T; Vrdoljak-Mozetic D; Versa-Ostojić D; Krasević M; Stifter S; Audy-Jurković S
    Cytopathology; 2006 Dec; 17(6):382-9. PubMed ID: 17168922
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patterns of stromal invasion in ovarian serous tumors of low malignant potential (borderline tumors): a reevaluation of the concept of stromal microinvasion.
    McKenney JK; Balzer BL; Longacre TA
    Am J Surg Pathol; 2006 Oct; 30(10):1209-21. PubMed ID: 17001150
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [ZNF217 gene was detected in ovarian serous cystadenocarcinoma by fluorescence in situ hybridization].
    Zhong M; Li J; Ding YQ; Song LL
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2006 Dec; 23(6):665-7. PubMed ID: 17160949
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Well-differentiated serous neoplasms of the ovary.
    Longacre TA; Kempson RL; Hendrickson MR
    Pathology (Phila); 1993; 1(2):255-306. PubMed ID: 9420921
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytopathology of serous neoplasia of the ovary and the peritoneum: differential diagnosis from mesothelial proliferations.
    Pisharodi LR; Bedrossian CW
    Diagn Cytopathol; 1996 Nov; 15(4):292-5. PubMed ID: 8982583
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Nucleolus organizers in the epithelium of serous ovarian tumors].
    Iakovtsova II
    Tsitol Genet; 1995; 29(5):38-41. PubMed ID: 8721844
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Clinicopathologic analysis and expression of cyclin D1 and p53 of ovarian borderline tumors and carcinomas].
    Shao HL; Shen DH; Xue WC; Li Y; Yu YZ
    Zhonghua Fu Chan Ke Za Zhi; 2007 Apr; 42(4):227-32. PubMed ID: 17631760
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DNA fragmentation factor (DFF45): expression and prognostic value in serous ovarian cancer.
    Brustmann H
    Pathol Res Pract; 2006; 202(10):713-20. PubMed ID: 16962250
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic value of measurements of angiogenesis in serous carcinoma of the ovary.
    Palmer JE; Sant Cassia LJ; Irwin CJ; Morris AG; Rollason TP
    Int J Gynecol Pathol; 2007 Oct; 26(4):395-403. PubMed ID: 17885489
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of mRNAs for type I and type III procollagens in serous ovarian cystadenomas and cystadenocarcinomas.
    Kauppila S; Saarela J; Stenbäck F; Risteli J; Kauppila A; Risteli L
    Am J Pathol; 1996 Feb; 148(2):539-48. PubMed ID: 8579116
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High expression of tissue inhibitor of metalloproteinase-2 in serous ovarian carcinomas and the role of this expression in ovarian tumorigenesis.
    Kim TJ; Rho SB; Choi YL; Choi CH; Lee JW; Bae DS; Ahn G; Lee JH; Kim BG
    Hum Pathol; 2006 Jul; 37(7):906-13. PubMed ID: 16784992
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Myeloid and lymphoid dendritic cells in the peritoneal fluid of women with ovarian cancer.
    Wertel F; Polak G; Roliński J; Barczyński B; Kotarski J
    Adv Med Sci; 2006; 51():174-7. PubMed ID: 17357302
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Diagnostic difficulties in serous "borderline" tumors of the ovary].
    Vereczkey I; Tóth E; Orosz Z
    Magy Onkol; 2009 Mar; 53(1):23-31. PubMed ID: 19318323
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Maspin expression and localization impact on angiogenesis and prognosis in ovarian cancer.
    Solomon LA; Munkarah AR; Schimp VL; Arabi MH; Morris RT; Nassar H; Ali-Fehmi R
    Gynecol Oncol; 2006 Jun; 101(3):385-9. PubMed ID: 16443262
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Correlation between serious ovarian tumors and extra-ovarian peritoneal tumors of the same histology].
    Kunz J; Rondez R
    Praxis (Bern 1994); 1998 Feb; 87(6):191-8. PubMed ID: 9531813
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The relevance of angiogenesis in benign and malignant epithelial tumors of the ovary: a quantitative histologic study.
    Brustmann H; Riss P; Naudé S
    Gynecol Oncol; 1997 Oct; 67(1):20-6. PubMed ID: 9345351
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.